Protein language models enable prediction of polyreactivity of monospecific, bispecific, and heavy-chain-only antibodies [0.03%]
蛋白质语言模型能够预测单特异性、双特异性及仅重链抗体的多反应性
Xin Yu,Kostika Vangjeli,Anusha Prakash et al.
Xin Yu et al.
Background: Early assessment of antibody off-target binding is essential for mitigating developability risks such as fast clearance, reduced efficacy, toxicity, and immunogenicity. The baculovirus particle (BVP) binding a...
A case study of a bispecific antibody manufacturability assessment and optimization during discovery stage and its implications [0.03%]
一种双特异性抗体在发现阶段的可制造性分析和优化的案例研究及其影响
Shuang Wang,Weijie Zhang,Baotian Yang et al.
Shuang Wang et al.
The manufacturability assessment and optimization of bispecific antibodies (bsAbs) during the discovery stage are crucial for the success of the drug development process, impacting the speed and cost of advancing such therapeutics to the In...
Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity [0.03%]
一种针对HER2的携带伊利替康（Eribulan）并具有强旁观者效应和ICD作用的抗体药物偶联物BB-1701的临床前研究
Yang Wang,Bing Xia,Lixia Cao et al.
Yang Wang et al.
Background: Several HER2-targeting antibody-drug conjugates (ADC) have gained market approval for the treatment of HER2-expressing metastasis. Promising responses have been reported with the new generation of ADCs in pati...
A VHH single-domain platform enabling discovery and development of monospecific antibodies and modular neutralizing bispecifics against SARS-CoV-2 variants [0.03%]
一种VHH单域平台，能够发现并开发针对SARS-CoV-2变异体的单一特异性抗体和模块化双特异性中和抗体
Marisa L Yang,Tom Z Yuan,Kara Y Chan et al.
Marisa L Yang et al.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, escape coronavirus disease 2019 therapeutics and vaccines, and jeopardize public health. To combat SARS-CoV-2 antigenic escape, we developed a rapid, high-thr...
Correction to: Role of antibody engineering in generation of derivatives starting from MOv19 MAb: 40 years of biological/therapeutic tools against folate receptor alfa [0.03%]
关于抗体工程在MOv19单克隆抗体衍生物生成中的作用的更正：针对叶酸受体阿尔法的40年生物/治疗工具发展历程
[This corrects the article DOI: 10.1093/abt/tbac026.]. © The Author(s) 2024. Published by Oxford University Press on behalf of Antibody Therapeutics.
Published Erratum
Antibody therapeutics. 2024 May 15;7(2):187. DOI:10.1093/abt/tbae010 2024
An integrated database of experimentally validated major histocompatibility complex epitopes for antigen-specific cancer therapy [0.03%]
一个实验验证的抗原特异性癌症治疗的主要组织相容性复合体表位整合数据库
Satoru Kawakita,Aidan Shen,Cheng-Chi Chao et al.
Satoru Kawakita et al.
Cancer immunotherapy represents a paradigm shift in oncology, offering a superior anti-tumor efficacy and the potential for durable remission. The success of personalized vaccines and cell therapies hinges on the identification of immunogen...
A new mechanism of antibody diversity: formation of the natural antibodies containing LAIR1 and LILRB1 extracellular domains [0.03%]
抗体多样性的一种新机制：含有LAIR1和LILRB1胞外区的天然型抗体的产生
Yuanzhi Chen,Zhiren Zeng,Ziyou Chen et al.
Yuanzhi Chen et al.
The recent discovery of public antibodies targeting Plasmodium falciparum-encoded repetitive interspersed families of polypeptides (RIFINs), which contain extracellular immunoglobulin-like domains from LAIR1 or LILRB1, constitutes a signifi...
Correction to: Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate [0.03%]
固态肿瘤治疗改革的纠正：较小格式抗体-药物偶联物的新兴潜力的修正版
[This corrects the article DOI: 10.1093/abt/tbae005.]. © The Author(s) 2024. Published by Oxford University Press on behalf of Antibody Therapeutics.
Published Erratum
Antibody therapeutics. 2024 Jun 17;7(2):188. DOI:10.1093/abt/tbae015 2024
Structure and function of therapeutic antibodies approved by the US FDA in 2023 [0.03%]
2023年美国FDA批准的治疗性抗体的结构与功能
William R Strohl
William R Strohl
In calendar year 2023, the United States Food and Drug Administration (US FDA) approved a total of 55 new molecular entities, of which 12 were in the class of therapeutic antibodies. Besides antibody protein drugs, the US FDA also approved ...
Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate [0.03%]
实体瘤治疗革新：小型抗体药物偶联物的新兴潜力
Xiaojie Ma,Mingkai Wang,Tianlei Ying et al.
Xiaojie Ma et al.
In recent years, substantial therapeutic efficacy of antibody-drug conjugates (ADCs) has been validated through approvals of 16 ADCs for the treatment of malignant tumors. However, realization of the maximum clinical use of ADCs requires su...